Ortec Targeting Late 1999 Launch Of Cultured Skin Product Under HDE
This article was originally published in The Gray Sheet
Ortec International is hoping to release its Composite Cultured Skin for the management of chronic ulcers in patients with junctional and dystrophic forms of epidermolysis bullosa in late 1999 following a recent humanitarian use designation from FDA.
You may also be interested in...
Ortec will launch its OrCel wound care product for three FDA-cleared indications once the cryopreserved tissue gains marketing approval in the late spring for venous leg ulcer treatment, the firm says
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.